BioSpace News Archive

Expects to Report EVOMELA® (melphalan for injection) Fourth Quarter 2020 Unaudited Revenue of Approximately $4.8 Million and Full-Year 2020 Unaudited Revenue of Approximately $15 Million, exceeding guidance

AmMax Bio, Inc. announced that Larry Hsu, Ph.D., Chief Executive Officer and the management team will participate in one-on-one meetings with investors at the 41st Annual Cowen Health Care Conference on Wednesday, March 3, 2021.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene ® platform.

Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity. McDavid Stilwell has been appointed to succeed Dr. Viret as CFO. “It has been a sincere pleasure working with Jean over more than six years as we have built Coherus into a growing commercial-stage biotech company. He will alw

- The FDA has granted Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation to FBX-101 for treatment of patients with Krabbe disease - FBX-101 is a first-in-human gene therapy utilizing an adeno-associated virus (AAV) to deliver a functioning copy of the GALC gene intraveniously to cells in the central nervous system (CNS) and peripheral organs

Blue Cross Blue Shield of Massachusetts (Blue Cross) announced today its perfect score of 100 on the 2021 Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices

Marketing campaign includes the brand’s first-ever commercial spot introducing women to a birth control that puts them in control of their body, their sex life, and their pregnancy prevention.

Prometheus Biosciences, Inc. (“Prometheus”), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the appointments of Judith L. Swain , MD and Helen C Adams to its board of directors

Dewpoint Therapeutics , the biomolecular condensates company, today announced that it has appointed Regina Barzilay , Ph.D., to its Board of Directors.

Thermo Fisher Scientific, the world leader in serving science, today launched the Thermo Scientific Helios 5 PXL PFIB Wafer DualBeam.